ALK-IN-1 (Standard)
ALK-IN-1 (Standard) is the analytical standard of ALK-IN-1 (Brigatinib analog) (HY-13464). This product is intended for research and analytical applications. ALK-IN-1 is an ALK and EGFR inhibitor. ALK-IN-1 binds to and inhibits ALK kinase, ALK fusion proteins, and wild-type and mutant EGFR variants, thereby disrupting their corresponding signaling pathways. ALK-IN-1 can suppress the growth and proliferation of tumor cells and exhibits potential inhibitory activity against mutant EGFR. ALK-IN-1 can be used in the research of non-small-cell lung cancer.
For research use only. We do not sell to patients.
- CAS No.: 1197958-12-5
- Formula: C26H34ClN6O2P
- Molecular Weight:529.01
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Product Information
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 1197958-12-5
-
Molecular Weight 529.01
-
Formula C26H34ClN6O2P
-
SMILES
CP(C)(C1=CC=CC=C1NC2=NC(NC3=CC=C(N4CCC(N(C)C)CC4)C=C3OC)=NC=C2Cl)=O
-
Synonyms
Brigatinib analog (Standard)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[2]. Fang H, et al. Design, synthesis and evaluation of the Brigatinib analogues as potent inhibitors against tertiary EGFR mutants (EGFRdel19/T790M/C797S and EGFRL858R/T790M/C797S). Bioorg Med Chem Lett. 2022 Sep 15;72:128729. [Content Brief]
[3]. Li B, et al. Simultaneous Quantification of Brigatinib and Brigatinib-Analog in Rat Plasma and Brain Homogenate by LC-MS/MS: Application to Comparative Pharmacokinetic and Brain Distribution Studies. Int J Anal Chem. 2019;2019:9028309. Published 2019 Dec 5. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)